AGL 38.70 Increased By ▲ 0.20 (0.52%)
AIRLINK 137.88 Increased By ▲ 0.99 (0.72%)
BOP 5.43 Increased By ▲ 0.03 (0.56%)
CNERGY 3.78 No Change ▼ 0.00 (0%)
DCL 7.74 Decreased By ▼ -0.14 (-1.78%)
DFML 45.62 Decreased By ▼ -0.18 (-0.39%)
DGKC 80.50 Increased By ▲ 0.15 (0.19%)
FCCL 29.55 Increased By ▲ 0.65 (2.25%)
FFBL 55.80 Decreased By ▼ -1.20 (-2.11%)
FFL 9.09 Decreased By ▼ -0.34 (-3.61%)
HUBC 105.60 Increased By ▲ 1.86 (1.79%)
HUMNL 14.05 Increased By ▲ 0.08 (0.57%)
KEL 4.30 Increased By ▲ 0.58 (15.59%)
KOSM 8.23 Decreased By ▼ -0.01 (-0.12%)
MLCF 37.98 Increased By ▲ 0.58 (1.55%)
NBP 69.23 Increased By ▲ 0.83 (1.21%)
OGDC 167.00 Increased By ▲ 0.40 (0.24%)
PAEL 25.20 Increased By ▲ 0.19 (0.76%)
PIBTL 6.78 Decreased By ▼ -0.27 (-3.83%)
PPL 130.35 Increased By ▲ 0.99 (0.77%)
PRL 23.76 Increased By ▲ 0.09 (0.38%)
PTC 15.70 Decreased By ▼ -0.15 (-0.95%)
SEARL 61.48 Increased By ▲ 0.68 (1.12%)
TELE 7.04 Increased By ▲ 0.03 (0.43%)
TOMCL 36.10 Increased By ▲ 0.21 (0.59%)
TPLP 7.81 Decreased By ▼ -0.05 (-0.64%)
TREET 15.15 Increased By ▲ 0.09 (0.6%)
TRG 44.89 Decreased By ▼ -0.01 (-0.02%)
UNITY 25.51 Increased By ▲ 0.11 (0.43%)
WTL 1.27 Increased By ▲ 0.04 (3.25%)
BR100 9,229 Increased By 28.2 (0.31%)
BR30 27,790 Increased By 229.9 (0.83%)
KSE100 86,467 Increased By 409.1 (0.48%)
KSE30 27,163 Increased By 118.7 (0.44%)

LAHORE: Getz Pharma manufactures safe and efficacious medicines in its WHO, PIC/s, and EAEU pre-qualified manufacturing facility, a spokesman of the company, said.

Responding to false information about its product Risek IV 40 mg injection on electronic and social media, the spokesman said. “On February 12, 2024, the Federal Inspector of Drugs-IV, while conducting market surveillance in Moro, Sindh, identified counterfeit Risek 40mg IV injections at the premises of M/s Qalanari Medicos on Hospital Road, Moro, Nowsheroferoz.

Samples were sent for testing, including confirmation by Getz Pharma. We confirmed the sample as counterfeit, not manufactured by us, and provided a comparative analysis report to authorities, urging action.”

Getz Pharma condemns the misreporting by the electronic media of the Alert issued by Drug Regulatory Authority of Pakistan (DRAP) as if our manufactured product was deemed spurious or counterfeit, requiring recall.

Copyright Business Recorder, 2024

Comments

Comments are closed.